



**Propiconazole/Pydiflumetofen**

**Propiconazole/Pydiflumetofen SE (A21573C) -  
Local Lymph Node Assay (LLNA) in Mice**

**Final Report**

**DATA REQUIREMENT(S):** OECD 429 (2010)  
EPA 870.2600 (2003)  
EC Directive No. 440/2008

**AUTHOR(S):** Jennifer Durando, BS

**COMPLETION DATE:** April 16, 2018

**PERFORMING LABORATORY:** Product Safety Labs  
2394 Highway 130  
Dayton, NJ 08810 USA

**LABORATORY PROJECT ID:** Report Number: 46821  
Study Number: 46821  
Task Number: TK0186807

**SPONSOR(S):** Syngenta Crop Protection, LLC  
410 Swing Road  
Post Office Box 18300  
Greensboro, NC 27419-8300 USA

**VOLUME 1 OF 1 OF STUDY**

**PAGE 1 OF 42**

## STATEMENT OF DATA CONFIDENTIALITY CLAIMS

### STATEMENT OF NO DATA CONFIDENTIALITY CLAIMS UNDER SPECIFIED FIFRA PROVISIONS

No claim of confidentiality, on any basis whatsoever, is made for any information contained in this document. I acknowledge that information not designated as within the scope of FIFRA sec. 10(d)(1)(A), (B), or (C) and which pertains to a registered or previously registered pesticide is not entitled to confidential treatment and may be released to the public, subject to the provisions regarding disclosure to multinational entities under FIFRA 10(g).

Company: Syngenta Crop Protection, LLC  
410 Swing Road  
Post Office Box 18300  
Greensboro, NC 27419-8300 USA

Submitter: Adora Clark  
Adora Clark, Ph.D.

Date: April 24, 2018

Syngenta is the owner of this information and data. Syngenta has submitted this material to the United States Environmental Protection Agency specifically under the provisions contained in FIFRA as amended and, hereby, consents to use and disclosure of this material by EPA according to FIFRA. In submitting this material to EPA according to method and format requirements contained in PR Notice 2011-3, we do not waive any protection or right involving this material that would have been claimed by the company if this material had not been submitted to the EPA, nor do we waive any protection or right provided under FIFRA Section 3 (concerning data exclusivity and data compensation) or FIFRA Section 10(g) (prohibiting disclosure to foreign and multinational pesticide companies or their agents).

## GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

This study meets the requirements OECD Principles of GLP (as revised in 1997): ENV/MC/CHEM(98)17, OECD, Paris, 1998; U.S. EPA GLP (FIFRA): 40 CFR Part 160, 1989; Japanese Ministry of Agriculture, Forestry and Fisheries: No. 23-Syouan-5173, 2 February, 2012; and EC Directive 2004/10/EC, Official Journal of the European Union, L50/44, Feb. 20, 2004 with the following exception: The stability, uniformity of mixture and verification of concentration of alpha-Hexylcinnamaldehyde (HCA), purity  $\geq$  95%, in its carriers were not determined..


Specific information related to the characterization of the test substance as received and tested is the responsibility of the study Sponsor (see Test Substance section).

I, the undersigned, declare that the methods, results and data contained in this report faithfully reflect the procedures used and raw data collected during the study.

  
Jennifer Durando, BS  
Study Director, Product Safety Labs

04/10/2018  
Date

Performing Laboratory: Product Safety Labs  
2394 Highway 130  
Dayton, NJ 08810 USA

  
Monique Inforzato, BS  
Representative of Submitter/Sponsor

04/24/2018  
Date

Submitter/Sponsor: Syngenta Crop Protection, LLC  
410 Swing Road  
Post Office Box 18300  
Greensboro, NC 27419-8300 USA

**FLAGGING STATEMENT**

This page is intentionally left blank.

## QUALITY ASSURANCE STATEMENT

The Product Safety Labs' Quality Assurance Unit has reviewed this final study report to assure the report accurately describes the methods and standard operating procedures, and that the reported results accurately reflect the raw data of the study.

QA activities for this study:

QA Activity	Performed By	Date Conducted	Date Findings Reported To Study Director And Management
Protocol review	A. Adamiec; B. Simms	Apr 3, 2017 <sup>1</sup> ; Dec 4, 2017	Apr 3, 2017; Dec 4, 2017
Critical phase inspection: <i>Day 1 sample preparation for test and control groups</i>	A. Villagran	Nov 15, 2017	Nov 15, 2017
Raw data audit	B. Simms	Dec 4, 2017	Dec 4, 2017
Draft report review	B. Simms	Dec 4, 2017	Dec 4, 2017

Final report reviewed by:




---

Barbara Simms  
Quality Assurance Auditor  
Product Safety Labs

04/16/2018

---

Date

<sup>1</sup> PSL's "generic" protocol used for this study was reviewed by the Quality Assurance group on this date.

## GENERAL INFORMATION

### Contributors

The following contributed to this report in the capacities indicated:

Name	Title
Jennifer Durando, BS	Study Director
Monique Inforzato, BS	Syngenta Study Monitor
Shannon Stevens, BS	Primary Scientist
Cynthia Bodnar	Scientist
Harry Maselli, ALAT	Scientist
Matthew Sorber, BS	Scientist

### Study dates

Study initiation date: October 26, 2017

Experimental start date: November 8, 2017

Experimental termination date: November 21, 2017

### Deviations from the Guidelines

None

### Amendment to Final Protocol

Clarification: Is the documentation of the methods of synthesis/fabrication of the test substance located at your facility as listed about in section I.

Yes.

Due to a technical oversight the about information was inadvertently not provided on the protocol cover form at the time of preparation. This amendment will provide the necessary information.

### Deviations from Final Protocol

None

### Retention of samples

The test substance is retained for at least 3 months following submission of the final report, unless otherwise specified by the Sponsor. All remaining test substance will be returned to the Sponsor or properly disposed. Records of sample disposition are maintained by Product Safety Labs (PSL).

## **Other**

Information on care of the test system, equipment maintenance and calibration, storage, usage, and disposition of the test substance, and all other records that would demonstrate adherence to the protocol will be maintained. Facility records which are not specific to the subject study will be maintained by the testing facility and archived according to PSL SOP.

The original signed final report and electronic copies (in Microsoft Word and pdf) of the final report, including the signed QA and GLP Compliance pages will be sent to the Sponsor. A copy of the signed report, together with the protocol (P327 SYN) and all raw data generated at PSL, is maintained in the PSL Archives in Notebook No. 46821: pages 1-72. PSL will maintain these records for a period of at least five years. After this time, the Sponsor will be offered the opportunity to take possession of the records or request continued archiving by PSL.

Any electronic raw data generated is maintained on-site in accordance with GLP archiving procedures.

## **Performing laboratory test substance reference number**

171023-2H

## TABLE OF CONTENTS

<b>STATEMENT OF DATA CONFIDENTIALITY CLAIMS .....</b>	<b>2</b>
<b>GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT .....</b>	<b>3</b>
<b>FLAGGING STATEMENT.....</b>	<b>4</b>
<b>QUALITY ASSURANCE STATEMENT .....</b>	<b>5</b>
<b>GENERAL INFORMATION .....</b>	<b>6</b>
<b>TABLE OF CONTENTS .....</b>	<b>8</b>
<b>1.0 EXECUTIVE SUMMARY .....</b>	<b>10</b>
1.1 Study Design .....	10
1.2 Results .....	10
1.3 Conclusion .....	10
<b>2.0 INTRODUCTION.....</b>	<b>11</b>
2.1 Purpose.....	11
2.2 Regulatory Guidelines.....	11
2.3 Test Facility.....	11
<b>3.0 MATERIALS AND METHODS .....</b>	<b>11</b>
3.1 Test Substance.....	11
3.2 <sup>3</sup> H-methyl Thymidine.....	12
3.3 Experimental Design.....	12
3.4 Preparation of Test Substance .....	14
3.5 Preliminary Toxicity Testing .....	14
3.6 Selection of Animals/Dose Levels .....	14
3.7 Sample Preparation .....	14
3.8 Test Substance Application.....	15
3.9 Dermal Scoring .....	15
3.10 Ear Thickness Measurements.....	15
3.11 <sup>3</sup> H-methyl Thymidine Injections.....	15
3.12 Lymph Node Assessment.....	15
3.13 Clinical Observations .....	16
3.14 Body Weights.....	16
3.15 Evaluation .....	16
3.16 Historical Positive Control Validation Study.....	16
3.17 Statistical Analysis .....	17
<b>4.0 RESULTS AND DISCUSSION .....</b>	<b>17</b>
<b>5.0 CONCLUSIONS .....</b>	<b>18</b>

<b>6.0</b>	<b>REFERENCES.....</b>	<b>18</b>
	<b>TABLES SECTION.....</b>	<b>20</b>
TABLE 1	Preliminary Group Body Weights.....	21
TABLE 2	Preliminary Group Testing Scores.....	22
TABLE 3	Preliminary Group Ear Thickness Measurements (mm).....	23
TABLE 4	Preliminary Group Individual Cage-Side Observations .....	24
TABLE 5	Individual Body Weights .....	25
TABLE 6	Individual Body Weights Historical Positive Control Validation Study .....	26
TABLE 7	Individual Dermal Irritation Scores .....	27
TABLE 8	Individual Dermal Irritation Scores Historical Positive Control Validation Study .....	29
TABLE 9	Individual Cage-Side Observations .....	30
TABLE 10	Individual Cage-Side Observations Historical Positive Control Validation Study .....	34
TABLE 11	Individual Dpm Values .....	35
TABLE 12	Individual Dpm Values Historical Positive Control Validation Study .....	36
TABLE 13	Stimulation Index.....	37
TABLE 14	Stimulation Index Historical Positive Control Validation Study.....	38
TABLE 15	Primary Skin Irritation Scoring System .....	39
	<b>APPENDICES SECTION .....</b>	<b>40</b>
APPENDIX 1	Certificate of Analysis.....	41

## 1.0 EXECUTIVE SUMMARY

### 1.1 Study Design

A local lymph node assay (LLNA) was conducted with mice to examine the dermal sensitization potential for Propiconazole/Pydiflumetofen SE (A21573C).

Two concentrations (25% and 50%) of the test substance in 1% Pluronic<sup>®</sup> L92 Surfactant w/w in distilled water (1% Pluronic<sup>®</sup> L92), the neat test substance (100%) and the vehicle alone were topically applied to sixteen healthy test mice (4 mice/group) for three consecutive days. Three days after the last application, 250 µL of sterile phosphate buffered saline (PBS) containing 20 µCi of <sup>3</sup>H-methyl thymidine was injected intravenously via the tail vein of each mouse. Approximately five hours later, all animals were euthanized via an overdose of inhaled Isoflurane and the draining (auricular) lymph nodes were harvested and prepared for analysis in a scintillation counter. The results are presented in disintegrations per minute per mouse (dpm/mouse). Each animal's ears were also evaluated for erythema and edema prior to each application and again on Day 6, prior to the IV injection.

The sensitivity of the procedure was validated using recent historical positive control data (Study 46092). A positive control group (four animals) was maintained under the same environmental conditions and treated in the same manner as the test and vehicle control animals. The positive control group animals were treated with a 25% (w/w) mixture of alpha-hexylcinnamaldehyde (HCA), purity ≥ 95%, in 1% Pluronic<sup>®</sup> L92.

### 1.2 Results

A table summarizing the sensitization results noted is found below:

	Mean DPM	Stimulation Index <sup>1</sup>
Group 1 - Vehicle Control	2048.72	–
Group 2 - 25% Test Substance	2813.22	1.37
Group 3 - 50% Test Substance	3148.54	1.54
Group 4 - 100% Test Substance	3822.31	1.87

### 1.3 Conclusion

Based on the results of this study, Propiconazole/Pydiflumetofen SE (A21573C) is not considered to be a contact dermal sensitizer in the LLNA. Proper conduct of the LLNA was confirmed via a positive response with 25% alpha-Hexylcinnamaldehyde, purity ≥ 95% (HCA), a moderate contact sensitizer.

---

<sup>1</sup> The stimulation index is derived by dividing the dpm of each experimental group by the dpm of the vehicle control group. A stimulation index of greater than or equal to 3.0 generally indicates a positive response.

## **2.0 INTRODUCTION**

### **2.1 Purpose**

This study was conducted to determine the potential for Propiconazole/Pydiflumetofen SE (A21573C) to elicit a dermal sensitization reaction.

### **2.2 Regulatory Guidelines**

The procedures as described in this protocol are based on the most recent version of the following testing guidelines:

- OECD Guidelines for the Testing of Chemicals, Test No. 429 (2010)
- U.S. EPA Health Effects Test Guidelines, OPPTS 870.2600 (2003)
- Official Journal of the European Communities. Methods for the Determination of Toxicity and Health Effects, Part B.42 (Skin Sensitization: Local Lymph Node Assay) Commission Regulation (EC) No. 440/2008

### **2.3 Test Facility**

This study was conducted at Product Safety Labs' test facility at 2394 US Highway 130, Dayton, New Jersey 08810. In the opinion of the Sponsor and the Study Director, this study did not unnecessarily duplicate any previous work.

## **3.0 MATERIALS AND METHODS**

### **3.1 Test Substance**

The test substance was identified as: Propiconazole/Pydiflumetofen SE  
A21573C  
Batch ID 1007839

It was received on October 23, 2017, and was further identified with PSL Reference Number 171023-2H. The test substance was stored at room temperature. Documentation of the methods of synthesis, fabrication, or derivation of the test substance is retained by the Sponsor (see Amendment).

Characterization of the test substance was provided to PSL by the Sponsor (see Appendix 1):

Composition: Pydiflumetofen (151 g/L), 13.7% w/w  
Propiconazole (128 g/L), 11.6% w/w

Physical Description: Beige liquid

Stability: Test substance was expected to be stable for the duration of testing.

Recertification Date: End of October 2020

### **3.2 <sup>3</sup>H-methyl Thymidine**

<sup>3</sup>H-methyl Thymidine, Lot No. 201711, was received on November 16, 2017 and stored refrigerated. Documentation of the methods of synthesis, fabrication, or derivation is retained by PerkinElmer, Inc., Boston, MA.

The following information related to the characterization of the radioisotope was provided on the Technical Data Sheet:

Specific Activity: 20 Ci/mmol

Molecular Weight: 242

Radioactive Concentration: 37 MBq/mL; 1.0 mCi/mL

Radiochemical Purity: > 97% (HPLC)

Thymine Content: < 0.5%

Expiration Date: December 16, 2017

### **3.3 Experimental Design**

#### **3.3.1 Animals**

Species/Strain: Mouse, CBA/J

Number of Animals: 17

Number of Groups: 5

Number of Animals per Group:

Preliminary Irritation: 1

Test (3 groups): 4 per group

Vehicle (Negative) Control: 4

Sex: Female, nulliparous and non-pregnant.

Age: Preliminary Animals: Young adult (11-12 weeks)

Age/Body Weight: Test and Control Animals: Young adult (11-12 weeks)/19.6-24.4 grams at experimental start.

Source: Received from Envigo RMS Inc. on October 18, 2017 (Preliminary Irritation Animals) and on October 25, 2017 (Test Control Group and Test Group Animals).

### **3.3.2 Husbandry**

Housing: The animals were individually housed in plastic solid bottom cages during the dosing and resting phase of the study. After final weighing until sacrifice, animals were housed in their respective dose groups in plastic cages with bedding. Enrichment (e.g., nesting material) was placed in each cage. Bedding in the plastic, solid bottom cages was changed at least once per week. All caging conformed to the size recommendations in the most recent *Guide for the Care and Use of Laboratory Animals* (Natl. Res. Council, 2011).

Animal Room Temperature: 20-23°C

Animal Room Relative Humidity: 40-48%

Animal Room Air Changes: 13/hour. Airflow measurements are evaluated regularly and the records are kept on file at PSL.

Photoperiod: 12-hour light/dark cycle

Acclimation Period: 21 days

### **3.3.3 Food and feeding**

Food: Envigo Teklad Global 16% Protein Rodent Diet<sup>®</sup> #2016. The diet was available *ad libitum*.

Water: Filtered tap water was supplied *ad libitum*.

Contaminants: There were no known contaminants reasonably expected to be found in the food or water at levels which would have interfered with the results of this study. Analyses of the food and water are conducted regularly and the records are kept on file at PSL.

### **3.3.4 Identification**

Cage: Each cage was identified with a cage card indicating at least the study number, identification, and sex of the animal.

Animal: Each animal was marked with a color code and given a sequential animal number assigned to study 46821, which constituted unique identification. Only the sequential animal number is presented in this report.

### 3.4 Preparation of Test Substance

The test substance as received (neat) was mixed well prior to use. Solubility testing conducted by PSL indicated that the test substance was soluble in 1% Pluronic<sup>®</sup> L92. All preparations were mixed well prior to dosing.

### 3.5 Preliminary Toxicity Testing

One mouse was treated with the test substance at the maximum concentration suitable for application (100%). The ears of the mouse were evaluated for erythema and edema immediately prior to dosing on Days 1, 2, 3, and on Day 6 according to the scoring system described in Table 15. Body weight measurements were taken on Days 1 and 6. Ear thickness measurements were taken on Day 1 (pre-dose), Day 3 and Day 6.

Twenty-five  $\mu\text{L}$  of the test substance was applied to the dorsum of both ears of the mouse once per day for three consecutive days. Application was done using an appropriate size micropipette to accurately deliver 25  $\mu\text{L}$ . The dose was gently spread as evenly as possible over the dorsal surface of the ear using the disposable pipette tip. No treatment was made on Days 4 and 5. On Day 6, each site was evaluated for local reactions (erythema & edema).

The animal was observed daily for signs of toxicity. The Study Director used this data in conjunction with any pre-existing data to select the three concentrations to be tested. The test substance at 25% and 50% (w/w) mixtures in 1% Pluronic<sup>®</sup> L92 and the test substance at 100% were selected for test.

### 3.6 Selection of Animals/Dose Levels

Prior to dosing, the animals were weighed and the ears were checked for any abnormalities or clinical signs of diseases or injury. Sixteen healthy, naive female mice without pre-existing ear irritation were selected and distributed (four mice per group) into the following groups:

Group #	Purpose	Concentration %
1	Vehicle Control	0
2	Test Substance	25
3	Test Substance	50
4	Test Substance	100

Concentrations were selected based on toxicity, solubility, irritancy, and viscosity.

### 3.7 Sample Preparation

Concentrations of 25%, 50% and 100% were selected for the main test based on results of the preliminary screening test. Dilutions of the test substance were prepared as w/w mixtures in 1% Pluronic<sup>®</sup> L92. The vehicle control, 1% Pluronic<sup>®</sup> L92 was also prepared. All dosage preparations were freshly prepared on the day of application.

### 3.8 Test Substance Application

Beginning on Day 1, a quantity of 25 µL of the appropriate test substance concentration or the vehicle alone was applied to the dorsum of both ears of each mouse once per day for three consecutive days (Days 1, 2, and 3) using a micropipette. During application, the material was gently spread as evenly as possible over the dorsal surface of the ear using the micro-pipette tip.

### 3.9 Dermal Scoring

Prior to each application (Days 1, 2, and 3) and on Day 6, the ears were evaluated for erythema and edema according to the modified Draize scoring system (Draize, Woodard, & Calvary, 1944; see Table 15).

### 3.10 Ear Thickness Measurements

Duplicate measurements of each animal's ears were made using a micrometer. The measurements were made at the apex of the pinna. Measurements were taken on the preliminary screen animal on Days 1 (pre-dose), Day 3 and Day 6. The % ear swelling was calculated for each ear using the following equation:

$$\% \text{ Ear swelling} = \frac{(B - A)}{A} \times 100\% \text{ where:}$$

A = ear thickness measurement on Day 1 (mm x 10<sup>-2</sup>)

B = ear thickness measurement on Day 3 or 6 (mm x 10<sup>-2</sup>)

### 3.11 <sup>3</sup>H-methyl Thymidine Injections

On Day 6 of the study (three days after the final topical application) 250 µL of sterile phosphate buffered saline (PBS) containing 20 µCi of <sup>3</sup>H-methyl thymidine was injected intravenously via the tail vein of each mouse.

### 3.12 Lymph Node Assessment

Approximately five hours after the injection, all test and control mice were euthanized via overdose of inhaled Isoflurane and the draining auricular lymph nodes from all animals were excised. The lymph nodes were evaluated for each individual mouse. A single cell suspension of lymph node cells (LNC) was prepared in PBS by gently massaging the lymph nodes between the frosted ends of two microscope slides over a collection vessel. The slides were then rinsed briefly with PBS into the vessel. The contents of the vessel were transferred to a centrifuge tube and washed with an excess of PBS and centrifuged for approximately 10 minutes at 1800 rpm, with an RCF<sup>1</sup> of 489G. This process was carried out twice. In both cases, the supernatant was decanted and discarded following each centrifugation. After the second wash, 5 mL of the 5% trichloroacetic acid (TCA) in distilled water was then added to

---

<sup>1</sup> Relative Centrifugal Force.

the sediment and the tube was vortexed briefly. The DNA was then precipitated in the 5% TCA in distilled water at approximately 4°C overnight (approximately 18 hours).

Following the overnight precipitation of the DNA, the tubes were centrifuged again for approximately 10 minutes at 1800 rpm and the supernatant was discarded. The resulting precipitate was re-suspended using 1 mL of the 5% TCA in distilled water and transferred to 10 mL of scintillation fluid. Incorporation of <sup>3</sup>H-methyl thymidine was measured by β-scintillation counting and expressed as disintegrations per minute, minus background dpm.

### **3.13 Clinical Observations**

All test, control and preliminary mice were observed for signs of mortality, gross toxicity, and/or behavioral changes daily (See Tables 4 and 9). Preliminary mice were euthanized via CO<sub>2</sub> inhalation and all test and control mice were euthanized via overdose of inhaled Isoflurane (an anesthetic) on Day 6.

### **3.14 Body Weights**

Individual body weight of the preliminary animal was recorded on Day 1 (initial) shortly before test substance application and prior to sacrifice on Day 6. Individual body weights of test and control animals were recorded on Day 1 (initial) shortly before test substance application and prior to IV injections of <sup>3</sup>H-methyl thymidine on test Day 6.

### **3.15 Evaluation**

The mean and standard deviation of the dpm values were calculated for each dose group. A stimulation index (SI) was derived for each experimental group by dividing the mean dpm of each experimental group by the mean dpm of the vehicle control group. Any test substance that produces an SI ≥ 3 in the LLNA is normally considered “positive” for dermal sensitization potential (Kimber et al., 1994).

The EC3 value was not calculated since all dose levels induced a stimulation index of less than 3.0.

### **3.16 Historical Positive Control Validation Study**

The procedures used in this study were validated using alpha-hexylcinnamaldehyde, purity ≥ 95% (HCA) as the positive control substance, namely 25% (w/w) mixture of HCA in 1% Pluronic<sup>®</sup> L92. The most recent validation, PSL Study # 46092, was performed by PSL between August 2 and 8, 2017. A copy of the signed report, together with the protocol and all raw data generated at PSL, are maintained in the PSL Archives in Notebook No. 46092: pages 1-46. This test was conducted at the Dayton Facility with CBA/J mice from Envigo RMS following procedures similar to those described in Sections 3.8 through 3.15. The results obtained from this testing are presented below.

**Historical Vehicle Control Group – 1% Pluronic® L92:** No dermal irritation was observed for any of the historical vehicle control group sites.

**Historical Positive Control Group – 25% (w/w) HCA in 1% Pluronic® L92:** Very slight erythema (score of 1) was evident at seven historical positive control sites on Day 2 and at all sites on Days 3 and 6. Slight edema (score of 1) was present at seven sites on Day 3 and at six sites on Day 6. Desquamation was present at all sites on Day 6.

Number of positive control sites with dermal irritation

Day	Erythema				Edema	
	Very slight (score of 1)	Well-defined (score of 2)	Moderate to Severe (score of 3)	Severe (score of 4)	Slight (score of 1)	Marked (score of 2)
2	7/8	0/8	0/8	0/8	0/8	0/8
3	8/8	0/8	0/8	0/8	7/8	0/8
6	8/8	0/8	0/8	0/8	6/8	0/8

The positive control (HCA) at 25% produced a dermal sensitization response in mice (SI = 6.38).

### 3.17 Statistical Analysis

Statistical analysis was performed. Significance was judged at  $p < 0.05$ . The treated groups and negative vehicle control group were compared using a One-Way Analysis of Variance (ANOVA), followed by comparison of the treated groups to control by Dunnett's t-test for multiple comparisons (INSTAT Biostatistics, Graph Pad Software, San Diego, CA). Outlier analysis was conducted using Grubbs' test (Grubbs, 1969).

## 4.0 RESULTS AND DISCUSSION

Preliminary irritation body weights, testing scores, ear thickness measurements and individual cage-side observations are presented in Tables 1-4. Individual body weights for vehicle, test, and historical positive control animals are presented in Table 5-6. Individual dermal irritation scores are presented in Table 7-8. Individual cage-side observations are presented in Table 9-10. Individual dpm values are presented in Table 11-12. A summary of results for vehicle control, test, and historical positive control animals is presented in Table 13-14. The Draize Primary Skin Irritation Scoring System is presented in Table 15. The Certificate of Analysis is presented in Appendix 1.

All animals appeared active and healthy throughout the study. Three mice from the vehicle control and eleven mice in the test substance groups lost body weight during the study. All other mice gained body weight during the study.

Group 1 (Vehicle Control – 1% Pluronic<sup>®</sup> L92): No dermal irritation was observed for any of the vehicle control group sites.

Group 2 (25% Test Substance in 1% Pluronic<sup>®</sup> L92): No dermal irritation was observed for any of the test group sites.

Group 3 (50% Test Substance in 1% Pluronic<sup>®</sup> L92): No dermal irritation was observed for any of the test group sites.

Group 4 (100% Test Substance in 1% Pluronic<sup>®</sup> L92): Very slight erythema (score of 1) was observed at one test site on Day 2 and at three sites on Day 3.

Treatment of mice with 25%, 50% and 100% of Propiconazole/Pydiflumetofen SE (A21573C) resulted in stimulation index values of 1.37, 1.54 and 1.87, respectively. As a stimulation index (SI) of less than 3.0 was observed in all the treatment groups, the test substance was not considered positive for a dermal sensitization potential.

## 5.0 CONCLUSIONS

Based on these findings and on the evaluation system used, Propiconazole/Pydiflumetofen SE (A21573C) is not considered to be a contact dermal sensitizer in the LLNA.

The positive response observed in the historical positive control validation study with 25% alpha-Hexylcinnamaldehyde (HCA), purity  $\geq$  95%, validated the test system used in this study (see Section 3.16).

## 6.0 REFERENCES

Boverhof, D. R., Wiescinski, C. M., Botham, P., Lees, D., Debruyne, E., Repetto-Larsay, M., Ladics, G., Hoban, D., Gamer, A., Remmele, M., Wang-Fan, W., Ullmann, L. G., Mehta, J., Billington, R. & Woolhiser, M. R. (2008). Interlaboratory validation of 1% Pluronic<sup>®</sup> L92 surfactant as a suitable, aqueous vehicle for testing pesticide formulations using the murine local lymph node assay. *Toxicol. Sci.* 105(1), 79-85.

Draize, J.H., Woodward, G., & Calvery, H.O. (1944). Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. *J. Pharmacol. Exp. Ther.*, 82, 377-390.

Grubbs, F. E. (1969). Procedures for Detecting Outlying Observations in Samples. *Technometrics*, 11(1), 1-21.

Kimber, I., Dearman, R. J., Scholes, E. W., & Basketter, D. A. (1994). The local lymph node assay: developments and applications. *Toxicology*, 93, 13-31.

National Research Council. (2011). *Guide for the Care and Use of Laboratory Animals* (8<sup>th</sup> ed.). Washington, DC: The National Academies Press.

Ryan, C.A., Cruse, L.W., Skinner, R.A., Dearman, R.J., Kimber, I., & Gerberick, G.F. (2002). Examination of a vehicle for use with water soluble materials in the murine local lymph node assay. *Food Chem. Toxicol.*, 40, 1719-1725.

## **TABLES SECTION**

**TABLE 1      Preliminary Group Body Weights**

<b>Animal No.</b>	<b>Sex</b>	<b>Body Weight (g)</b>	
		<b>Day 1</b>	<b>Day 6</b>
<b>Group 1P - 100%</b>			
3680	F	21.1	21.4

**TABLE 2      Preliminary Group Testing Scores**

**Erythema/Edema**

Animal No.	Sex	Day							
		1		2		3		6	
		Left	Right	Left	Right	Left	Right	Left	Right
<b>Group 1P - 100%<sup>1</sup></b>									
3680	F	0/0	0/0	0/0 <sup>2</sup>	0/0 <sup>2</sup>	0/0 <sup>2</sup>	0/0 <sup>2</sup>	0/0	0/0 <sup>2</sup>

<sup>1</sup> 25 µL of the test substance was applied as received to each ear (50 µL total).

<sup>2</sup> Test substance residue at the dose site.

**TABLE 3 Preliminary Group Ear Thickness Measurements (mm)****Erythema/Edema****Preliminary Animal (Left Ear)**

<b>Dose Level</b>	<b>Group No.</b>	<b>Animal No.</b>	<b>Day 1 1<sup>st</sup></b>	<b>Day 1 2<sup>nd</sup></b>	<b>Mean Thickness Day 1</b>	<b>Day 3 1<sup>st</sup></b>	<b>Day 3 2<sup>nd</sup></b>	<b>Mean Thickness Day 3</b>	<b>% Change Days 1- 3</b>	<b>Day 6 1<sup>st</sup></b>	<b>Day 6 2<sup>nd</sup></b>	<b>Mean Thickness Day 6</b>	<b>% Change Days 1-6</b>
100% Test Substance	1P	3680	0.27	0.26	0.27	0.31	0.30	0.31	14.81%	0.29	0.28	0.29	7.41%

**Preliminary Animal (Right Ear)**

<b>Dose Level</b>	<b>Group No.</b>	<b>Animal No.</b>	<b>Day 1 1<sup>st</sup></b>	<b>Day 1 2<sup>nd</sup></b>	<b>Mean Thickness Day 1</b>	<b>Day 3 1<sup>st</sup></b>	<b>Day 3 2<sup>nd</sup></b>	<b>Mean Thickness Day 3</b>	<b>% Change Days 1- 3</b>	<b>Day 6 1<sup>st</sup></b>	<b>Day 6 2<sup>nd</sup></b>	<b>Mean Thickness Day 6</b>	<b>% Change Days 1-6</b>
100% Test Substance	1P	3680	0.26	0.26	0.26	0.32	0.29	0.31	19.23%	0.28	0.29	0.29	11.54%

**TABLE 4 Preliminary Group Individual Cage-Side Observations**

Animal Number	Animal Sex	Group	Dose Conc. (%)	Observation	Day of Observation (x=observation is present)					
					1	2	3	4	5	6
3680	F	1P	100	Active and healthy	x	x	x	x	x	x



**TABLE 5 Individual Body Weights**

<b>Animal No.</b>	<b>Group</b>	<b>Sex</b>	<b>Day 1 (g)</b>	<b>Day 6 (g)</b>
3601	1 Vehicle Control (1% Pluronic® L92)	F	23.6	22.9
3602		F	22.8	21.4
3603		F	19.6	19.9
3604		F	23.7	22.3
3605	2 25% Test Substance in 1% Pluronic® L92	F	20.7	19.8
3606		F	23.3	21.9
3607		F	23.8	22.1
3608		F	22.0	23.1
3609	3 50% Test Substance in 1% Pluronic® L92	F	23.0	22.8
3610		F	20.8	20.4
3611		F	21.9	21.8
3612		F	23.6	23.4
3613	4 100% Test Substance	F	22.0	21.0
3614		F	21.5	20.5
3615		F	24.4	24.3
3616		F	21.2	21.0

**TABLE 6 Individual Body Weights Historical Positive Control Validation Study<sup>1</sup>**

<b>Animal No.</b>	<b>Group</b>	<b>Sex</b>	<b>Day 1 (g)</b>	<b>Day 6 (g)</b>
3701	1 Vehicle Control (1% Pluronic <sup>®</sup> L92)	F	19.9	20.2
3702		F	19.7	20.0
3703		F	20.1	21.0
3704		F	20.1	20.9
3705	2 Positive Control (25% HCA in 1% Pluronic <sup>®</sup> L92)	F	22.9	22.6
3706		F	18.8	19.3
3707		F	20.1	20.1
3708		F	19.2	18.5

---

<sup>1</sup> PSL Study # 46092, testing was performed by PSL between August 2 and 8, 2017.

**TABLE 7 Individual Dermal Irritation Scores****Group 1 – Vehicle Control<sup>1</sup>****Erythema/Edema**

Animal No.	Sex	Days							
		1		2		3		6	
		Left	Right	Left	Right	Left	Right	Left	Right
3601	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3602	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3603	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3604	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0

**Group 2 – 25% Test Substance<sup>2</sup>****Erythema/Edema**

Animal No.	Sex	Days							
		1		2		3		6	
		Left	Right	Left	Right	Left	Right	Left	Right
3605	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3606	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3607	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3608	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0

<sup>1</sup> 25 µL of 1% Pluronic<sup>®</sup> L92 was applied to each ear (50 µL total).

<sup>2</sup> 25 µL of the test substance was applied as a w/w mixture in 1% Pluronic<sup>®</sup> L92 to each ear (50 µL total).

**TABLE 7 Individual Dermal Irritation Scores (Continued)**

**Group 3 – 50% Test Substance<sup>1</sup>**

**Erythema/Edema**

Animal No.	Sex	Days							
		1		2		3		6	
		Left	Right	Left	Right	Left	Right	Left	Right
3609	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3610	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3611	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3612	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0

**Group 4 – 100% Test Substance<sup>2</sup>**

**Erythema/Edema**

Animal No.	Sex	Days							
		1		2		3		6	
		Left	Right	Left <sup>3</sup>	Right <sup>3</sup>	Left <sup>3</sup>	Right <sup>3</sup>	Left	Right
3613	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3614	F	0/0	0/0	1/0	0/0	1/0	1/0	0/0	0/0
3615	F	0/0	0/0	0/0	0/0	1/0	0/0	0/0 <sup>3</sup>	0/0 <sup>3</sup>
3616	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0 <sup>3</sup>	0/0 <sup>3</sup>

<sup>1</sup> 25 µL of the test substance was applied as a w/w mixture in 1% Pluronic<sup>®</sup> L92 to each ear (50 µL total).

<sup>2</sup> 25 µL of the test substance was applied as received to each ear (50 µL total).

<sup>3</sup> Test substance residue at the dose site(s).

**TABLE 8 Individual Dermal Irritation Scores Historical Positive Control Validation Study<sup>1</sup>**

**Group 1 – Vehicle Control<sup>2</sup>**

**Erythema/Edema**

Animal No.	Sex	Days							
		1		2		3		6	
		Left	Right	Left	Right	Left	Right	Left	Right
3701	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3702	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3703	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
3704	F	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0

**Group 2 – Positive Control<sup>3</sup>**

**Erythema/Edema**

Animal No.	Sex	Days							
		1		2		3		6	
		Left	Right	Left	Right	Left	Right	Left <sup>4</sup>	Right
3705	F	0/0	0/0	1/0	1/0	1/1	1/1	1/1	1/1 <sup>4</sup>
3706	F	0/0	0/0	1/0	0/0	1/1	1/0	1/1	1/0
3707	F	0/0	0/0	1/0	1/0	1/1	1/1	1/1	1/0 <sup>4</sup>
3708	F	0/0	0/0	1/0	1/0	1/1	1/1	1/1	1/1 <sup>4</sup>

<sup>1</sup> PSL Study # 46092, testing was performed by PSL between August 2 and 8, 2017.

<sup>2</sup> 25 µL of 1% Pluronic<sup>®</sup> L92 was applied to each ear (50 µL total).

<sup>3</sup> 25 µL of a 25% w/w mixture of HCA in 1% Pluronic<sup>®</sup> L92 was applied to each ear (50 µL total).

<sup>4</sup> Desquamation at the dose site(s).

**TABLE 9 Individual Cage-Side Observations**

Animal Number	Animal Sex	Group	Dose Conc. (%)	Observation	Day of Observation (x=observation is present)					
					1	2	3	4	5	6
3601	F	1	Vehicle Control (1% Pluronic <sup>®</sup> L92)	Active and healthy	x	x	x	x	x	x
3602	F	1	Vehicle Control (1% Pluronic <sup>®</sup> L92)	Active and healthy	x	x	x	x	x	x
3603	F	1	Vehicle Control (1% Pluronic <sup>®</sup> L92)	Active and healthy	x	x	x	x	x	x
3604	F	1	Vehicle Control (1% Pluronic <sup>®</sup> L92)	Active and healthy	x	x	x	x	x	x

**TABLE 9 Individual Cage-Side Observations (Continued)**

Animal Number	Animal Sex	Group	Dose Conc. (%)	Observation	Day of Observation (x=observation is present)					
					1	2	3	4	5	6
3605	F	2	25% Test Substance in 1% Pluronic® L92	Active and healthy	x	x	x	x	x	x
3606	F	2	25% Test Substance in 1% Pluronic® L92	Active and healthy	x	x	x	x	x	x
3607	F	2	25% Test Substance in 1% Pluronic® L92	Active and healthy	x	x	x	x	x	x
3608	F	2	25% Test Substance in 1% Pluronic® L92	Active and healthy	x	x	x	x	x	x

**TABLE 9 Individual Cage-Side Observations (Continued)**

Animal Number	Animal Sex	Group	Dose Conc. (%)	Observation	Day of Observation (x=observation is present)					
					1	2	3	4	5	6
3609	F	3	50% Test Substance in 1% Pluronic® L92	Active and healthy	x	x	x	x	x	x
3610	F	3	50% Test Substance in 1% Pluronic® L92	Active and healthy	x	x	x	x	x	x
3611	F	3	50% Test Substance in 1% Pluronic® L92	Active and healthy	x	x	x	x	x	x
3612	F	3	50% Test Substance in 1% Pluronic® L92	Active and healthy	x	x	x	x	x	x

**TABLE 9 Individual Cage-Side Observations (Continued)**

Animal Number	Animal Sex	Group	Dose Conc. (%)	Observation	Day of Observation (x=observation is present)					
					1	2	3	4	5	6
3613	F	4	100% Test Substance	Active and healthy	x	x	x	x	x	x
3614	F	4	100% Test Substance	Active and healthy	x	x	x	x	x	x
3615	F	4	100% Test Substance	Active and healthy	x	x	x	x	x	x
3616	F	4	100% Test Substance	Active and healthy	x	x	x	x	x	x

**TABLE 10 Individual Cage-Side Observations Historical Positive Control Validation Study<sup>1</sup>**

Animal Number	Animal Sex	Group	Dose Conc. (%)	Observation	Day of Observation (x=observation is present)					
					1	2	3	4	5	6
3701	F	1	Vehicle Control (1% Pluronic <sup>®</sup> L92)	Active and healthy	x	x	x	x	x	x
3702	F	1	Vehicle Control (1% Pluronic <sup>®</sup> L92)	Active and healthy	x	x	x	x	x	x
3703	F	1	Vehicle Control (1% Pluronic <sup>®</sup> L92)	Active and healthy	x	x	x	x	x	x
3704	F	1	Vehicle Control (1% Pluronic <sup>®</sup> L92)	Active and healthy	x	x	x	x	x	x
3705	F	2	Positive Control (25% HCA in 1% Pluronic <sup>®</sup> L92)	Active and healthy	x	x	x	x	x	x
3706	F	2	Positive Control (25% HCA in 1% Pluronic <sup>®</sup> L92)	Active and healthy	x	x	x	x	x	x
3707	F	2	Positive Control (25% HCA in 1% Pluronic <sup>®</sup> L92)	Active and healthy	x	x	x	x	x	x
3708	F	2	Positive Control (25% HCA in 1% Pluronic <sup>®</sup> L92)	Active and healthy	x	x	x	x	x	x

<sup>1</sup> PSL Study # 46092, testing was performed by PSL between August 2 and 8, 2017.

**TABLE 11 Individual Dpm<sup>1</sup> Values**

Background:	51.19						
Group	Animal #	dpm	dpm minus background <sup>2</sup>	Group Mean DPM	Std. Dev	SI <sup>3</sup>	SI ≥ 3
1 Vehicle Control (1% Pluronic <sup>®</sup> L92)	3601	2452.27	2401.08	2048.72	238.20	-	-
	3602	2035.68	1984.49				
	3603	1941.20	1890.01				
	3604	1970.49	1919.30				
2 25% Test Substance in 1% Pluronic <sup>®</sup> L92	3605	3231.99	3180.80	2813.22	369.75	1.37	No
	3606	2458.87	2407.68				
	3607	2649.03	2597.84				
	3608	3117.73	3066.54				
3 50% Test Substance in 1% Pluronic <sup>®</sup> L92	3609	2650.80	2599.61	3148.54	410.13	1.54	No
	3610	3218.56	3167.37				
	3611	3641.48	3590.29				
	3612	3288.08	3236.89				
4 100% Test Substance	3613	3790.51	3739.32	3822.31	148.77	1.87	No
	3614	3912.42	3861.23				
	3615	4064.38	4013.19				
	3616	3726.67	3675.48				

<sup>1</sup> Disintegrations per minute.

<sup>2</sup> Values analyzed for outliers, Grubbs, 1969.

<sup>3</sup> Stimulation Index = Average dpm of Test Substance/Average dpm of Vehicle.

**TABLE 12 Individual Dpm<sup>1</sup> Values Historical Positive Control Validation Study<sup>2</sup>**

Background:	52.37						
Group	Animal #	dpm	dpm minus background <sup>3</sup>	Group Mean DPM	Std. Dev	SI <sup>4</sup>	SI ≥ 3
1 Vehicle Control (1% Pluronic <sup>®</sup> L92)	3701	2509.80	2457.43	2117.96	987.80	-	-
	3702	1788.77	1736.40				
	3703	1036.91	984.54				
	3704	3345.82	3293.45				
2 Positive Control (25% HCA in 1% Pluronic <sup>®</sup> L92)	3705	12570.42	12518.05	13520.15	729.75	6.38	Yes
	3706	13872.10	13819.73				
	3707	13565.37	13513.00				
	3708	14282.17	14229.80				

<sup>1</sup> Disintegrations per minute.

<sup>2</sup> PSL Study # 46092, testing was performed by PSL between August 2 and 8, 2017.

<sup>3</sup> Values analyzed for outliers, Grubbs, 1969.

<sup>4</sup> Stimulation Index = Average dpm of Test Substance/Average dpm of Vehicle.

**TABLE 13      Stimulation Index**

Group		Group Mean DPM	SI	Sensitization Response
Vehicle Control	1	2048.72	-	N/A
25% Test Substance	2	2813.22*	1.37	Not a Sensitizer
50% Test Substance	3	3148.54**	1.54	Not a Sensitizer
100% Test Substance	4	3822.31**	1.87	Not a Sensitizer

N/A= Not Applicable

\* Statistically significant difference from vehicle control,  $p < 0.05$ , by Dunnett's Multiple Comparisons Test.

\*\* Statistically significant difference from vehicle control,  $p < 0.01$ , by Dunnett's Multiple Comparisons Test

**TABLE 14      Stimulation Index Historical Positive Control Validation Study<sup>1</sup>**

Group		Group Mean DPM	SI	Sensitization Response
Vehicle Control	1	2117.96	-	N/A
Positive Control (25% HCA)	2	13520.15***	6.38	Positive – valid study

N/A= Not Applicable

\*\*\* Significant to control,  $p < 0.0001$  by unpaired t-test

---

<sup>1</sup> PSL Study # 46092, testing was performed by PSL between August 2 and 8, 2017.

**TABLE 15      Primary Skin Irritation Scoring System<sup>1</sup>**

<u>Evaluation of Skin Reactions</u>	<u>Value</u>
Erythema and eschar formation:	
No erythema.....	0
Very slight erythema (barely perceptible) .....	1
Well-defined erythema.....	2
Moderate to severe erythema .....	3
Severe erythema (beet redness) to slight eschar formation (injuries in depth).....	4
Edema formation:	
No edema .....	0
Slight edema (barely perceptible) .....	1
Marked edema (swelling is obvious) .....	2

---

<sup>1</sup> Modified from a published method (Draize, et al., 1944).

## APPENDICES SECTION

# APPENDIX 1 Certificate of Analysis



Syngenta Crop Protection, LLC  
Analytical and Product Chemistry  
Greensboro, NC 27409

## Certificate of Analysis

A21573C  
Batch ID 1007839 (GP170913)

Test Substance Name:	CGA64250/SYN545974 SE (125/150)
Common Name:	Propiconazole/Pydiflumetofen SE (125/150)
Design Code:	A21573C
Batch ID:	1007839
Other ID:	GP170913
Source:	Syngenta Crop Protection LLC., US ,410 Swing Road, Greensboro, NC 27409,

### Chemical Analysis

AI	% w/w	g/L
Pydiflumetofen	13.7	151
Propiconazole	11.6	128

Identity of the Active Ingredients: Confirmed

Methodology Used for Characterization: LC , mass spectrometry, oscillating density meter

The Active Ingredient(s) content is within the FAO limits,

### Isomer Assay

Analyte	Isomer	% w/w	g/L
CGA93590	1H-1,2,4-triazole, 1-([2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl)-, cis-	6.73	74
CGA93591	1H-1,2,4-triazole, 1-([2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl)-, trans-	4.84	53.2

## APPENDIX 1 Certificate of Analysis (Continued)

### Physical Analysis

Property	Value	Units
Density	1.100	g/cm <sup>3</sup>

Appearance: Beige liquid

Storage Temperature: <30°C

Re-certification Date: End of Oct/2020

*If stored under the conditions given above, this test substance can be considered stable until the recertification date is reached.*

The stability of this test substance will be determined concurrently through reanalysis of material held in inventory under GLP conditions at Syngenta Crop Protection, LLC, Greensboro, NC.

This Certificate of Analysis is summarizing data from a study that has been performed in compliance with Good Laboratory Practices per 40 CFR Part 160. Raw data, documentation, protocols, any amendments to study protocols and reports pertaining to this study are maintained in the Syngenta Crop Protection Archives in Greensboro, NC.

Study Number: USGR170462

Authorization: Kirt Durand

  
\_\_\_\_\_

Kirt Durand  
Analytical and Product Chemistry Department

Oct. 13, 2017

Date